(Q38110433)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1 reference

language of work or name

1 reference

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

855-868

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

Synthetic therapeutic peptides: science and market

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Therapeutic peptides: technological advances driving peptides into development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Therapeutic peptides revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Mechanistic determinants of biotherapeutics absorption following SC administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Lymphatic transport of proteins after s.c. injection: implications of animal model selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetics of gonadotropin-releasing hormone and its analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Clinical pharmacokinetics of depot leuprorelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Past, present, and future technologies for oral delivery of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Commercial challenges of protein drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Emerging Trends in Oral Delivery of Peptide and Protein Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Therapeutic application of peptides and proteins: parenteral forever?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Delivery of bioactive peptides and proteins across oral (buccal) mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Characterizing the impact of renal impairment on the clinical pharmacology of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Target-mediated drug disposition and dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Factors influencing the immunogenicity of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Innovative approaches to anti-arrhythmic drug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Strategies to improve plasma half life time of peptide and protein drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The LHRH antagonist cetrorelix: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Ipamorelin, the first selective growth hormone secretagogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Is lGnRH-III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Potent D-peptide inhibitors of HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Effect of pegylation on pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Development and characterization of novel erythropoiesis stimulating protein (NESP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmaceutical strategies utilizing recombinant human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Stapled peptide to enter human testing, but affinity questions remain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Concepts and challenges in quantitative pharmacology and model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic/pharmacodynamic studies in drug product development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Population pharmacokinetic studies in pediatrics: issues in design and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Physiologically based pharmacokinetic (PBPK) modeling in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Physiologically-based PK/PD modelling of therapeutic macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Population cell life span models for effects of drugs following indirect mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Clinical pharmacokinetics of cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

A mathematical model of the human menstrual cycle for the administration of GnRH analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0079-0

The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients

21 January 2018

1 reference

12 December 2020

Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling

1 reference

12 December 2020

Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences

1 reference

12 December 2020

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic comparison of desmopressin administered as whole, chewed and crushed tablets, and as an oral solution

1 reference

12 December 2020

Sandimmun neoral pharmacokinetics: impact of the new oral formulation.

1 reference

12 December 2020

Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue

1 reference

12 December 2020

A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial

1 reference

12 December 2020

Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines

1 reference

12 December 2020

Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties

1 reference

12 December 2020

Disposition of 14C-eptifibatide after intravenous administration to healthy men

1 reference

12 December 2020

10.1007/S40262-013-0079-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 March 2020

1026731644

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23719681%20AND%20SRC:MED&resulttype=core&format=json